The incorporation of circulating tumor DNA (ctDNA) testing into standard practice for patients with metastatic uveal melanoma receiving tebentafusp-tebn (Kimmtrak) may prov...

The American Association of Cancer Research (AACR) recently named a current and former member of the MRF Breakthrough Consortium as Fellows in the AACR Academy. MRF-support...

Guest blog post by Teddi Mellencamp Arroyave, TV Personality, Wellness Coach, host of the top-rated podcast Two Ts in a Pod, stage II melanoma survivor and advocate: The mo...

Washington, DC (April 20, 2023) – The Melanoma Research Foundation (MRF) is proud to announce the return of their Washington, DC Miles for Melanoma 5K event, held Sat...

An experimental mRNA vaccine developed by Moderna, Inc. and Merck shows significant potential to reduce the risk of recurrence or death in melanoma patients. According to c...

The New England Journal of Medicine (NEJM) recently published a major report announcing a treatment advancement for the melanoma community, particularly patients with rese...

In January, the Board of Directors welcomed its newest member, Kristina Baum, who has been a longtime advocate for the melanoma community. Kristina is a senior vice preside...

Written by MRF supporter, Sally Landenberger: Unfortunately, I became involved in the melanoma community through my son, Aaron’s, diagnosis and disease. It was not my cho...

Partnering with Your Team to Select Treatment for Newly Diagnosed Melanoma Live Date and Time: Wednesday, January 25 at 10:00 AM ET Washington, DC (January 18, 2023) –...

Scientific peer review of Congressionally Directed Medical Research Programs’ Melanoma Research Program for the Department of Defense The Congressionally Directed Med...

The MRF’s CURE Ocular Melanoma (CURE OM) initiative announces impactful data report assessing patient metrics to accelerate scientific understanding of this rare disease ...